Selected for National Project by the Ministry of Science and ICT
Joint Research Conducted with Chonnam National University and GIST
The National Immunotherapy Innovation Center (NIIC) at Chonnam National University, led by Professor Min Jeongjun of the Department of Nuclear Medicine at Hwasun Jeonnam National University Hospital, is launching the event of next-generation convergent immunotherapy platform applied sciences for the therapy of refractory cancers.
Min Jeongjun, Professor of Nuclear Medicine, Hwasun Jeonnam National University Hospital.
According to Hwasun Jeonnam National University Hospital on May 14, this analysis venture is a large-scale initiative chosen for the Ministry of Science and ICT’s ‘2026 Bio·Medical Technology Development Project (Next-Generation Bio).’ Chonnam National University and Gwangju Institute of Science and Technology (GIST) are collectively executing the venture.
The venture will run for 5 years, with a complete analysis funds of 30.7 billion gained. Of this, 24 billion gained will come from the nationwide funds, 6 billion gained from native authorities funds, and Chonnam National University and GIST will contribute round 700 million gained in matching funds.
The National Immunotherapy Innovation Center serves as a analysis hub situated within the Hwasun Vaccine Industry Special Zone in South Jeolla Province and can fulfill the function of a management tower overseeing the complete course of from analysis planning to commercialization.
This convergent analysis will set up an end-to-end analysis framework linked to the region-based bio-infrastructure, concurrently securing core immunotherapy applied sciences and laying the muse for industrialization.
The analysis goals to beat the constraints of present immune checkpoint inhibitors. It relies on the ‘SYMPHONY (Synthetic Multi-modality Platforms for Holistic ONco-immunotherapy)’ technique, which mixes Chonnam National University’s tumor microenvironment modulation expertise with GIST’s immune cell activation expertise.
The analysis group plans to concurrently apply next-generation drug improvement utilizing clever microorganisms, mRNA vaccines, nanomedicine, and antibody fragments, together with expertise to maximise immune cell operate. Through this, they purpose to transform so-called ‘chilly tumors,’ which present little to no immune response, into treatable situations.
Specifically, 5 key applied sciences will probably be utilized: AI-based anti-cancer microorganisms, multi-specific antibodies, hypoxia-improving nanoplatforms, mRNA neoantigen vaccines, and supramolecular lively particle (C-SMAP) expertise.
Professor Min Jeongjun, the principal investigator, said, “Through collaboration between researchers at Chonnam National University and GIST, we have established a research foundation that connects basic research to commercialization,” including, “We aim to secure global technological competitiveness in the bio market through the ‘SYMPHONY’ strategy, which combines proprietary Korean technologies.”
This content material was produced with the help of AI translation providers.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.